search
Back to results

A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
LY3502970
Dulaglutide
Placebo
Placebo
Sponsored by
Eli Lilly and Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Have been diagnosed with Type 2 Diabetes on diet and exercise and/or a stable dose of metformin
  • Have a stable body weight for the 3 months prior to randomization
  • Have a body mass index (BMI) ≥23 kilogram/square meter (kg/m²)
  • Males must agree to use highly effective methods of contraception
  • Women not of childbearing potential (WNOCBP) may participate in this trial
  • Note: Hormone replacement therapy in post-menopausal women is allowed but women must be on stable therapy for 3 months prior to day 1.

Exclusion Criteria:

  • Have Type 1 diabetes mellitus (T1DM) or history of ketoacidosis or hyperosmolar coma
  • Have a history of diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy that requires immediate treatment intervention
  • Have had more than 1 episode of severe hypoglycemia and aware of hypoglycemic symptoms
  • Have acute or chronic pancreatitis
  • Have obesity induced other endocrine disorders (Cushing's syndrome or Prader - Willi syndrome)
  • Have gastric emptying abnormality or chronically take medications impacting GI motility
  • Have poorly controlled hypertension
  • Have the following heart conditions within the last 6 months: myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack (TIA), cerebrovascular accident (stroke)or decompensated congestive heart failure, or IV heart failure
  • Have any symptoms of other liver diseases besides nonalcoholic fatty liver disease (NAFLD)
  • Have HIV, or Hepatitis B or Hepatitis C

Sites / Locations

  • Anaheim Clinical Trials, LLC
  • Velocity Clinical Research, Huntington Park
  • Velocity Clinical Research, Westlake
  • Rancho Cucamonga Clinical Research
  • Touro University California
  • New West Physicians Clinical Research
  • Optumcare Colorado Springs - Monument
  • Cotton O'Neil Clinical Research Center
  • Clinvest Research LLC
  • Premier Research
  • Intend Research, LLC
  • Capital Area Research, LLC
  • Family Medical Associates
  • Tristar Clinical Investigations
  • Dallas Diabetes Research Center
  • Biopharma Informatic, LLC
  • Bandera Family Health Care
  • Consano Clinical Research, LLC
  • Capital Clinical Research Center
  • Eastside Research Associates
  • Bugát Pál Kórház
  • Kanizsai Dorottya Korhaz
  • Zala Megyei Szent Rafael Kórház
  • Szent Margit Rendelőintézet Nonprofit Kft
  • Clinexpert Kft.
  • ClinDiab Kft.
  • TRANTOR'99 Bt. Anyagcsere Centrum
  • Strazsahegy Medicina Bt.
  • Wojewódzki Zespól Specjalistycznej Opieki Zdrowotnej
  • Gabinety TERPA
  • NZOZ Medica
  • Centralny Szpital Kliniczny MSWiA w Warszawie
  • Centrum Zdrowia Tuchów
  • Centrum Badan Klinicznych PI-House sp. z o.o.
  • Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna
  • NZOZ Przychodnia Specjalistyczna Andrzej Wittek, Henryk Rudzki
  • Dorado Medical Complex
  • Clinical Research Management Group Inc. - Hospital San Cristobal
  • BRCR Global Puerto Rico-Unda
  • Ambulancia diabetológie a porúch látkovej premeny a výživy - DIABEDA
  • Diabetol
  • MEDI-DIA s.r.o.
  • DIA-MED CENTRUM s.r.o.
  • Funkystuff

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Active Comparator

Placebo Comparator

Arm Label

3 milligrams (mg) LY3502970

12 mg LY3502970

24 mg LY3502970

36 mg LY3502970 - 1

36 mg LY3502970 - 2

45 mg LY3502970 - 1

45 mg LY3502970 - 2

1.5 mg Dulaglutide

Placebo

Arm Description

Participants received maintenance dose of 3 mg with dose escalation starting from 2 mg LY3502970 administered orally once daily (QD).

Participants received maintenance dose 12 mg with dose escalation starting from 2 mg, 6 mg and then 12 mg LY3502970 administered orally QD.

Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally QD.

Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.

Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.

Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.

Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.

Participants received 1.5 mg Dulaglutide administered subcutaneously (SC) once weekly (QW).

Participants received matching placebo.

Outcomes

Primary Outcome Measures

Change From Baseline in HbA1c in LY3502970 as Compared to Placebo
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Country + Baseline HbA1c Group (<=8.0%, >8.0%) + Treatment + Time + Treatment*Time (Type III sum of squares) as variables.

Secondary Outcome Measures

Change From Baseline in HbA1c in LY3502970 as Compared to Dulaglutide
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Country + Baseline HbA1c Group (<=8.0%, >8.0%) + Treatment + Time + Treatment*Time (Type III sum of squares) as variables.
Percentage of Participants With HbA1c ≤ 6.5%
Percentage of Participants with HbA1c ≤ 6.5%. Odds ratio was calculated using logistic regression model.
Percentage of Participants With HbA1c <7.0%
Percentage of Participants with HbA1c <7.0%. Odds ratio was calculated using logistic regression model.
Change From Baseline in Fasting Serum Glucose
Fasting glucose is a test to determine sugar levels in blood sample after an overnight fast. LS mean was determined by MMRM model with Baseline + Country + Baseline HbA1c Group (<=8.0%, 8.0%) + Treatment + Time + Treatment*Time (Type III sum of squares) as variables.
Change From Baseline in Body Weight
LS mean was determined by MMRM model with Baseline + Country + Baseline HbA1c Group (<=8.0%, >8.0%) + Treatment + Time + Treatment*Time (Type III sum of squares) as variables.
Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of LY3502970
PK: Steady State AUC of LY3502970

Full Information

First Posted
September 13, 2021
Last Updated
September 28, 2023
Sponsor
Eli Lilly and Company
search

1. Study Identification

Unique Protocol Identification Number
NCT05048719
Brief Title
A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
Official Title
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
September 15, 2021 (Actual)
Primary Completion Date
September 30, 2022 (Actual)
Study Completion Date
September 30, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eli Lilly and Company

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3502970 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 30 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
383 (Actual)

8. Arms, Groups, and Interventions

Arm Title
3 milligrams (mg) LY3502970
Arm Type
Experimental
Arm Description
Participants received maintenance dose of 3 mg with dose escalation starting from 2 mg LY3502970 administered orally once daily (QD).
Arm Title
12 mg LY3502970
Arm Type
Experimental
Arm Description
Participants received maintenance dose 12 mg with dose escalation starting from 2 mg, 6 mg and then 12 mg LY3502970 administered orally QD.
Arm Title
24 mg LY3502970
Arm Type
Experimental
Arm Description
Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally QD.
Arm Title
36 mg LY3502970 - 1
Arm Type
Experimental
Arm Description
Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
Arm Title
36 mg LY3502970 - 2
Arm Type
Experimental
Arm Description
Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
Arm Title
45 mg LY3502970 - 1
Arm Type
Experimental
Arm Description
Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
Arm Title
45 mg LY3502970 - 2
Arm Type
Experimental
Arm Description
Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
Arm Title
1.5 mg Dulaglutide
Arm Type
Active Comparator
Arm Description
Participants received 1.5 mg Dulaglutide administered subcutaneously (SC) once weekly (QW).
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants received matching placebo.
Intervention Type
Drug
Intervention Name(s)
LY3502970
Intervention Description
Administered orally
Intervention Type
Drug
Intervention Name(s)
Dulaglutide
Intervention Description
Administered subcutaneously
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Administered orally
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Administered subcutaneously
Primary Outcome Measure Information:
Title
Change From Baseline in HbA1c in LY3502970 as Compared to Placebo
Description
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Country + Baseline HbA1c Group (<=8.0%, >8.0%) + Treatment + Time + Treatment*Time (Type III sum of squares) as variables.
Time Frame
Baseline, Week 26
Secondary Outcome Measure Information:
Title
Change From Baseline in HbA1c in LY3502970 as Compared to Dulaglutide
Description
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Country + Baseline HbA1c Group (<=8.0%, >8.0%) + Treatment + Time + Treatment*Time (Type III sum of squares) as variables.
Time Frame
Baseline, Week 26
Title
Percentage of Participants With HbA1c ≤ 6.5%
Description
Percentage of Participants with HbA1c ≤ 6.5%. Odds ratio was calculated using logistic regression model.
Time Frame
Week 26
Title
Percentage of Participants With HbA1c <7.0%
Description
Percentage of Participants with HbA1c <7.0%. Odds ratio was calculated using logistic regression model.
Time Frame
Week 26
Title
Change From Baseline in Fasting Serum Glucose
Description
Fasting glucose is a test to determine sugar levels in blood sample after an overnight fast. LS mean was determined by MMRM model with Baseline + Country + Baseline HbA1c Group (<=8.0%, 8.0%) + Treatment + Time + Treatment*Time (Type III sum of squares) as variables.
Time Frame
Baseline, Week 26
Title
Change From Baseline in Body Weight
Description
LS mean was determined by MMRM model with Baseline + Country + Baseline HbA1c Group (<=8.0%, >8.0%) + Treatment + Time + Treatment*Time (Type III sum of squares) as variables.
Time Frame
Baseline, Week 26
Title
Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of LY3502970
Description
PK: Steady State AUC of LY3502970
Time Frame
Pre-dose (Week (wk) 0, wk 8, wk 12, and wk 26); Post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment).

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Have been diagnosed with Type 2 Diabetes on diet and exercise and/or a stable dose of metformin Have a stable body weight for the 3 months prior to randomization Have a body mass index (BMI) ≥23 kilogram/square meter (kg/m²) Males must agree to use highly effective methods of contraception Women not of childbearing potential (WNOCBP) may participate in this trial Note: Hormone replacement therapy in post-menopausal women is allowed but women must be on stable therapy for 3 months prior to day 1. Exclusion Criteria: Have Type 1 diabetes mellitus (T1DM) or history of ketoacidosis or hyperosmolar coma Have a history of diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy that requires immediate treatment intervention Have had more than 1 episode of severe hypoglycemia and aware of hypoglycemic symptoms Have acute or chronic pancreatitis Have obesity induced other endocrine disorders (Cushing's syndrome or Prader - Willi syndrome) Have gastric emptying abnormality or chronically take medications impacting GI motility Have poorly controlled hypertension Have the following heart conditions within the last 6 months: myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack (TIA), cerebrovascular accident (stroke)or decompensated congestive heart failure, or IV heart failure Have any symptoms of other liver diseases besides nonalcoholic fatty liver disease (NAFLD) Have HIV, or Hepatitis B or Hepatitis C
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Organizational Affiliation
Eli Lilly and Company
Official's Role
Study Director
Facility Information:
Facility Name
Anaheim Clinical Trials, LLC
City
Anaheim
State/Province
California
ZIP/Postal Code
92801
Country
United States
Facility Name
Velocity Clinical Research, Huntington Park
City
Huntington Park
State/Province
California
ZIP/Postal Code
90255
Country
United States
Facility Name
Velocity Clinical Research, Westlake
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
Rancho Cucamonga Clinical Research
City
Rancho Cucamonga
State/Province
California
ZIP/Postal Code
91730
Country
United States
Facility Name
Touro University California
City
Vallejo
State/Province
California
ZIP/Postal Code
94592
Country
United States
Facility Name
New West Physicians Clinical Research
City
Golden
State/Province
Colorado
ZIP/Postal Code
80401
Country
United States
Facility Name
Optumcare Colorado Springs - Monument
City
Monument
State/Province
Colorado
ZIP/Postal Code
80132
Country
United States
Facility Name
Cotton O'Neil Clinical Research Center
City
Topeka
State/Province
Kansas
ZIP/Postal Code
66606
Country
United States
Facility Name
Clinvest Research LLC
City
Springfield
State/Province
Missouri
ZIP/Postal Code
65807
Country
United States
Facility Name
Premier Research
City
Trenton
State/Province
New Jersey
ZIP/Postal Code
08611
Country
United States
Facility Name
Intend Research, LLC
City
Norman
State/Province
Oklahoma
ZIP/Postal Code
73069
Country
United States
Facility Name
Capital Area Research, LLC
City
Camp Hill
State/Province
Pennsylvania
ZIP/Postal Code
17011
Country
United States
Facility Name
Family Medical Associates
City
Levittown
State/Province
Pennsylvania
ZIP/Postal Code
19056
Country
United States
Facility Name
Tristar Clinical Investigations
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19114
Country
United States
Facility Name
Dallas Diabetes Research Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Facility Name
Biopharma Informatic, LLC
City
Houston
State/Province
Texas
ZIP/Postal Code
77084
Country
United States
Facility Name
Bandera Family Health Care
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78249
Country
United States
Facility Name
Consano Clinical Research, LLC
City
Shavano Park
State/Province
Texas
ZIP/Postal Code
78231
Country
United States
Facility Name
Capital Clinical Research Center
City
Olympia
State/Province
Washington
ZIP/Postal Code
98502
Country
United States
Facility Name
Eastside Research Associates
City
Redmond
State/Province
Washington
ZIP/Postal Code
98052
Country
United States
Facility Name
Bugát Pál Kórház
City
Gyongyos
State/Province
Heves
ZIP/Postal Code
3200
Country
Hungary
Facility Name
Kanizsai Dorottya Korhaz
City
Nagykanizsa
State/Province
Zala
ZIP/Postal Code
8800
Country
Hungary
Facility Name
Zala Megyei Szent Rafael Kórház
City
Zalaegerszeg
State/Province
Zala
ZIP/Postal Code
8900
Country
Hungary
Facility Name
Szent Margit Rendelőintézet Nonprofit Kft
City
Budapest
ZIP/Postal Code
1032
Country
Hungary
Facility Name
Clinexpert Kft.
City
Budapest
ZIP/Postal Code
1033
Country
Hungary
Facility Name
ClinDiab Kft.
City
Budapest
ZIP/Postal Code
1089
Country
Hungary
Facility Name
TRANTOR'99 Bt. Anyagcsere Centrum
City
Budapest
ZIP/Postal Code
1213
Country
Hungary
Facility Name
Strazsahegy Medicina Bt.
City
Budapest
ZIP/Postal Code
H1171
Country
Hungary
Facility Name
Wojewódzki Zespól Specjalistycznej Opieki Zdrowotnej
City
Wrocław
State/Province
Dolnośląskie
ZIP/Postal Code
50-403
Country
Poland
Facility Name
Gabinety TERPA
City
Lublin
State/Province
Lubelskie
ZIP/Postal Code
20-333
Country
Poland
Facility Name
NZOZ Medica
City
Lublin
State/Province
Lubelskie
ZIP/Postal Code
20-538
Country
Poland
Facility Name
Centralny Szpital Kliniczny MSWiA w Warszawie
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
02-507
Country
Poland
Facility Name
Centrum Zdrowia Tuchów
City
Wierzchosławice
State/Province
Małopolskie
ZIP/Postal Code
33-122
Country
Poland
Facility Name
Centrum Badan Klinicznych PI-House sp. z o.o.
City
Gdansk
State/Province
Pomorskie
ZIP/Postal Code
80-546
Country
Poland
Facility Name
Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna
City
Lodz
State/Province
Łódzkie
Country
Poland
Facility Name
NZOZ Przychodnia Specjalistyczna Andrzej Wittek, Henryk Rudzki
City
Ruda Slaska
State/Province
Śląskie
ZIP/Postal Code
41-709
Country
Poland
Facility Name
Dorado Medical Complex
City
Dorado
ZIP/Postal Code
00646
Country
Puerto Rico
Facility Name
Clinical Research Management Group Inc. - Hospital San Cristobal
City
Ponce
ZIP/Postal Code
00780
Country
Puerto Rico
Facility Name
BRCR Global Puerto Rico-Unda
City
San Juan
ZIP/Postal Code
00907
Country
Puerto Rico
Facility Name
Ambulancia diabetológie a porúch látkovej premeny a výživy - DIABEDA
City
Bratislava
State/Province
Bratislavský Kraj
ZIP/Postal Code
831 06
Country
Slovakia
Facility Name
Diabetol
City
Prešov
State/Province
Prešovský Kraj
ZIP/Postal Code
080 01
Country
Slovakia
Facility Name
MEDI-DIA s.r.o.
City
Sabinov
State/Province
Prešovský Kraj
ZIP/Postal Code
083 01
Country
Slovakia
Facility Name
DIA-MED CENTRUM s.r.o.
City
Puchov
State/Province
Trenčiansky Kraj
ZIP/Postal Code
020 01
Country
Slovakia
Facility Name
Funkystuff
City
Nove Zamky
ZIP/Postal Code
940 01
Country
Slovakia

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD Sharing Time Frame
Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD Sharing Access Criteria
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD Sharing URL
http://vivli.org/

Learn more about this trial

A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs